Mylan wins U.S. OK for generic hypertension drug

BOSTON, Feb 16 (Reuters) - Mylan Laboratories Inc. MYL.N has received final U.S. approval to market a generic version of Wyeth's (WYE.N) hypertension drug Inderal, Mylan said on Friday.

Mylan, which makes cheaper versions of marketed drugs, said it won approval from the U.S. Food and Drug Administration for propranolol hydrochloride extended-release capsules in 60 milligram, 80 milligram, 120 milligram and 160 milligram strengths.

Inderal had U.S. sales of about $201 million for the same strengths in 2006, Mylan said.

Par Pharmaceutical Cos. Inc. (PRX.N) last month also won approval for a generic version of the drug in the same dose strengths.

((Reporting by Toni Clarke, editing by John Wallace; Reuters messaging: toni.clarke.reuters.com@reuters.net)) Keywords: MYLAN/

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWEN4426